Glioblastoma Multiform

Oncology·MeSH: Neoplasm Recurrence, Local

Prevalence

5.0 / 100K

17 drugs in development·11 companies·1 clinical trial

Drug Pipeline by Phase

Phase 3(3)

Drug	Company
A10 and AS2-1 Antineoplaston	BURZYNSKI RESEARCH INSTITUTE INC (BZYR)
Antineoplastons (A10 & AS2-1)	BURZYNSKI RESEARCH INSTITUTE INC (BZYR)
Antineoplastons (A10 and AS2-1)	BURZYNSKI RESEARCH INSTITUTE INC (BZYR)

Phase 2(4)

Drug	Company
azixa	IMMUNE PHARMACEUTICALS INC (IMNP)
Berubicin	CNS Pharmaceuticals, Inc. (CNSP)
lomustine	CNS Pharmaceuticals, Inc. (CNSP)
lsta1	LISATA THERAPEUTICS, INC. (LSTA)

Phase 1(1)

Drug	Company
veledimex	Alaunos Therapeutics, Inc. (TCRT)

Preclinical(4)

Drug	Company
chi3l1 bsabs	Ocean Biomedical, Inc. (OCEA)
chi3l1 mab	Ocean Biomedical, Inc. (OCEA)
oncr-719	Oncorus, Inc. (ONCR)
TPI 287	CNS Pharmaceuticals, Inc. (CNSP)

BLA Filed(1)

Drug	Company
dcvax-l	NORTHWEST BIOTHERAPEUTICS INC (NWBO)

Phase 1/Phase 2(4)

Drug	Company
lomustine	VBI VACCINES INC/BC (VBIV)
perillyl alcohol	NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
temferon	Genenta Science S.p.A. (GNTA)
vbi-1901	VBI VACCINES INC/BC (VBIV)

BioSniper tracks 17 drugs in development for Glioblastoma Multiform across 11 companies.

There are 1 clinical trial targeting Glioblastoma Multiform tracked by BioSniper.

The estimated prevalence of Glioblastoma Multiform is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.